Rabia Gurses Ozden's Insider Trades & SAST Disclosures
Rabia Gurses Ozden's most recent trade in Adverum Biotechnologies Inc was a trade of 48,750 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 25, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Rabia Gurses Ozden.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adverum Biotechnologies Inc | Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 48,750 | 48,750 | - | - | Stock Option (Right to Buy) | |
| Adverum Biotechnologies Inc | Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 8,125 | 8,125 (0%) | 0% | 0 | Common Stock | |
| Adverum Biotechnologies Inc | Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 44,010 | 44,010 | - | - | Stock Option (Right to Buy) | |
| Adverum Biotechnologies Inc | Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Rabia Ozden Gurses | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Gurses Ozden Rabia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2024 | 66,633 | 159,400 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Gurses Ozden Rabia | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.86 per share. | 03 Feb 2024 | 6,346 | 153,054 (0%) | 0% | 4.9 | 30,842 | Common Stock |
| Ocular Therapeutix Inc | Gurses Rabia Ozden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.95 per share. | 31 Jan 2024 | 7,764 | 92,767 (0%) | 0% | 5.0 | 38,432 | Common Stock |
| Ocular Therapeutix Inc | Rabia Gurses Ozden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.93 per share. | 07 Jul 2023 | 832 | 100,531 (0%) | 0% | 4.9 | 4,102 | Common Stock |
| Adverum Biotechnologies Inc | Rabia Gurses Ozden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Rabia Gurses Ozden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.24 per share. | 06 Feb 2023 | 6,416 | 101,363 (0%) | 0% | 4.2 | 27,204 | Common Stock |
| Ocular Therapeutix Inc | Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 166,667 | 166,667 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 55,556 | 107,779 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Adverum Biotechnologies Inc | Rabia Gurses Ozden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges